Helmet Continuous Positive Airways Pressure (CPAP) treatment in a Non-Small Cell Lung Cancer (NSCLC) patient with severe hypoxemic respiratory failure due to gemcitabine therapy
Keywords:
gemcitabine toxicity, helmet cpap, respiratory failure, tossicità gemcitabina, cpap con caso, insufficienza respiratoriaAbstract
Gemcitabine is a pyrimidine analogue used worldwide for many solid tumours such as pancreatic cancer, ovarian cancer, non small cell lung cancer (NSCLC) and breast cancer. In this case report, we describe a patient who was treated with gemcitabine for NSCLC (poor differentiated squamous cell carcinoma) and who subsequently developed a severe respiratory failure with a radiological pattern of interstitial pneumoniae. Discontinuation of the drug, administration of corticosteroids and respiratory support are the mainstays of the treatment. Helmet Continuous Positive Airways Pressure (CPAP) allowed a prolonged, comfortable and safe treatment of the patient until the resolution of the acute respiratory failure. We think that helmet-CPAP could be a useful tool, even outside of intensive care unit, for the treatment of patients with severe interstitial pneumoniae due to gemcitabine therapy.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.